Miyake M, Nishimura N, Iemura Y et al (2025) Impact of initial relative dose intensity on tumor response and survival outcomes in enfortumab vedotin monotherapy for previously treated advanced urothelial carcinoma: a real-world analysis from a multicenter study. Clin Genitourin Cancer 23:102326

Article  PubMed  Google Scholar 

Rosenberg JE, O’Donnell PH, Balar AV et al (2019) Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. J Clin Oncol 37:2592–2600

Article  PubMed  PubMed Central  Google Scholar 

Powles T, Rosenberg JE, Sonpavde GP et al (2021) Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med 384:1125–1135

Article  PubMed  PubMed Central  Google Scholar 

Challita-Eid PM, Satpayev D, Yang P et al (2016) Enfortumab vedotin antibodydrug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res 76:3003–3013

Article  PubMed  Google Scholar 

Mooney K, Berry DL, Whisenant M et al (2017) Improving cancer care through the patient experience: how to use patient-reported outcomes in clinical practice. Am Soc Clin Oncol Educ Book 37:695–704

Article  PubMed  Google Scholar 

Degboe A, Ivanescu C, Rohay JM et al (2019) Validity and performance of the functional assessment of cancertherapy-bladder (FACT-Bl) among advanced urothelial cancer patients. Support Care Cancer 27:4189–4198

PubMed  PubMed Central  Google Scholar 

Jensen SE, Beaumont JL, Jacobsen PB et al (2013) Measuring priority symptoms in advancedbladder cancer: development and initial validation of a brief symptom index. J Support Oncol 11:86–93

PubMed  PubMed Central  Google Scholar 

Taarnhøj GA, Johansen C, Lindberg H et al (2020) Patient reported symptoms associated with qualityof life during chemo- or immunotherapy for bladder cancer patients with advanced disease. Cancer Med 9:3078–3087

Article  PubMed  PubMed Central  Google Scholar 

McGregor BA, O’Donnell PH, Balar A et al (2019) 921p-quality of life of metastatic urothelial cancer (mUC) patients treated with enfortumab vedotin (EV) following platinum-containing chemotherapy and a checkpoint inhibitor (CPI): data from EV-201 cohort 1. Ann Oncol 30(suppl5):v367–v368. https://doi.org/10.1093/annonc/mdz249.020

Article  Google Scholar 

Rosenberg JE, Mamtani R, Sonpavde GP et al (2024) Health-related quality of life in patients with previously treated advanced urothelial carcinoma from EV-301: a phase 3 trial of enfortumab vedotin versus chemotherapy. Eur Urol 85:574–585

Article  PubMed  PubMed Central  Google Scholar 

Alfred Witjes J, Max Bruins H, Carrión A et al (2024) European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: summary of the 2023 guidelines. Eur Urol 85:17–31

Article  PubMed  Google Scholar 

Minato A, Kimuro R, Ohno D et al (2023) Efficacy and tolerability of enfortumab vedotin for metastatic urothelial carcinoma: early experience in the real world. Anticancer Res 43:4055–4060

Article  PubMed  Google Scholar 

Miyake M, Nishimura N, Oda Y et al (2024) Longitudinal assessment of health-related quality of life in Japanese patients with advanced urothelial carcinoma receiving immune check point inhibitors. Sci Rep 14:23128

Article  PubMed  PubMed Central  Google Scholar 

Nishiyama H, Yamamoto Y, Sassa N et al (2020) Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial. Int J Clin Oncol 25:165–174

Article  PubMed  Google Scholar 

Norman GR, Sloan JA, Wyrwich KW (2003) Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 41:582–592

Article  PubMed  Google Scholar 

Doi Y, Minowa M, Uchiyama M et al (2000) Psychometric assessment of subjective sleep quality using the Japanese version of the Pittsburgh Sleep Quality Index (PSQI-J) in psychiatric disordered and control subjects. Psychiatry Res 97:165–172

Article  PubMed  Google Scholar 

Buysse DJ, Reynolds CF 3rd, Monk TH et al (1989) The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res 28:193–213

Article  PubMed  Google Scholar 

Hidese S, Ota M, Matsuo J et al (2023) Association between the Pittsburgh sleep quality index and white matter integrity in healthy adults: a whole-brain magnetic resonance imaging study. Sleep Biol Rhythms 21:249–256

Article  PubMed  PubMed Central  Google Scholar 

Nakamura N, Emoto T, Fukuhara Y et al (2024) Factors related to nocturia-specific quality of life in renal transplantation patients. Low Urin Tract Symptoms 16:e12517

Article  PubMed  Google Scholar 

Miyake M, Nishimura N, Oda Y et al (2025) Dysgeusia in patients with advanced urothelial carcinoma receiving enfortumab vedotin, platinum-based chemotherapy, or immune check point inhibitors: time-course assessment using chemotherapy-induced taste alteration scale. J Chemother 37:146–158

Article  PubMed  Google Scholar 

Kanda Y (2013) Investigation of the freely-available easy-to-use software “EZR” (Easy R) for medical statistics. Bone Marrow Transplant 48:452–458

Article  PubMed  Google Scholar 

Detry MA, Ma Y (2016) Analyzing repeated measurements using mixed models. JAMA 315:407–408

Article  PubMed  Google Scholar 

Vaughn DJ, Bellmunt J, Fradet Y et al (2018) Health-related quality-of-life analysis from KEYNOTE-045: a phase III study of pembrolizumab versus chemotherapy for previously treated advanced urothelial cancer. J Clin Oncol 36:1579–1587

Article  PubMed  Google Scholar 

Witjes JA, Galsky MD, Gschwend JE et al (2022) Health-related quality of life with adjuvant nivolumab after radical resection for high-risk muscle-invasive urothelial carcinoma: results from the phase 3 CheckMate 274 trial. Eur Urol Oncol 5:553–563

Article  PubMed  PubMed Central  Google Scholar 

Gupta S, Loriot Y, Van der Heijden MS et al (2025) Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study. Lancet Oncol 26:795–805

Article  PubMed  Google Scholar 

Jalali R, Rezaei M, Khaledi PB et al (2016) Sleep disorder and its correlates in patients undergoing chemotherapy. Iran J Nurs 29:76–85

Article  Google Scholar 

Coles T, Tan X, Bennett AV et al (2018) Sleep quality in individuals diagnosed with colorectal cancer: factors associated with sleep disturbance as patients transition off treatment. Psycho-Oncol 27:1050–1056

Article  Google Scholar 

Chen ML, Yu CT, Yang CH (2008) Sleep disturbances and quality of life in lung cancer patients undergoing chemotherapy. Lung Cancer 62:391–400

Article  PubMed  Google Scholar 

Gooneratne NS, Dean GE, Rogers AE et al (2007) Sleep and quality of life in long- term lung cancer survivors. Lung Cancer 58:403–410

Article  PubMed  Google Scholar 

Kahreh FS, Abdi A, Khatony A et al (2024) The effect of Jacobson relaxation technique on sleep quality of patients with cancer under chemotherapy: a randomized clinical trial. SAGE Open Nurs 10:23779608241286816

Article  PubMed  Google Scholar 

Jankovic J, Mazziotta JC, Pomeroy SL (2021) Bradley’s Neurology in Clinical Practice. Elsevier Health Sciences.